Log in

NASDAQ:OTLKOutlook Therapeutics Stock Price, Forecast & News

$0.75
+0.03 (+4.18 %)
(As of 05/25/2020 11:06 AM ET)
Add
Compare
Today's Range
$0.71
Now: $0.75
$0.75
50-Day Range
$0.56
MA: $0.68
$0.82
52-Week Range
$0.50
Now: $0.75
$3.20
Volume613,001 shs
Average Volume738,509 shs
Market Capitalization$68.34 million
P/E RatioN/A
Dividend YieldN/A
Beta0.09
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OTLK
CUSIPN/A
CIKN/A
Phone609-619-3990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.15 million
Book Value($0.56) per share

Profitability

Net Income$-34,520,000.00
Net Margins-423.83%

Miscellaneous

Employees56
Market Cap$68.34 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive OTLK News and Ratings via Email

Sign-up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions

How has Outlook Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Outlook Therapeutics' stock was trading at $0.6601 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OTLK stock has increased by 13.3% and is now trading at $0.7479. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Outlook Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Outlook Therapeutics.

When is Outlook Therapeutics' next earnings date?

Outlook Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Outlook Therapeutics.

How were Outlook Therapeutics' earnings last quarter?

Outlook Therapeutics, Inc. (NASDAQ:OTLK) announced its quarterly earnings results on Thursday, December, 19th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.19. The business earned $5.85 million during the quarter, compared to analyst estimates of $0.63 million. View Outlook Therapeutics' earnings history.

When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?

Outlook Therapeutics shares reverse split before market open on Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for OTLK?

4 analysts have issued 1 year price targets for Outlook Therapeutics' shares. Their forecasts range from $8.00 to $9.00. On average, they expect Outlook Therapeutics' stock price to reach $8.50 in the next year. This suggests a possible upside of 1,036.5% from the stock's current price. View analysts' price targets for Outlook Therapeutics.

Has Outlook Therapeutics been receiving favorable news coverage?

News coverage about OTLK stock has trended somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Outlook Therapeutics earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutOutlook Therapeutics.

Who are some of Outlook Therapeutics' key competitors?

What other stocks do shareholders of Outlook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Outlook Therapeutics investors own include Matinas BioPharma (MTNB), Amplify Energy (AMPY), Amplify Energy (AMPY), Acasti Pharma (ACST), AzurRx BioPharma (AZRX), Unum Therapeutics (UMRX), SCYNEXIS (SCYX), KushCo (KSHB), Polarityte (PTE) and Miragen Therapeutics (MGEN).

Who are Outlook Therapeutics' key executives?

Outlook Therapeutics' management team includes the following people:
  • Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec., Treasurer & Director (Age 53)
  • Dr. Pankaj Mohan, Founder & Director (Age 54)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)
  • Mr. Terry Dagnon, Chief Operating Officer (Age 57)
  • Rick Gregory, Director of Marketing & Communications

What is Outlook Therapeutics' stock symbol?

Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."

Who are Outlook Therapeutics' major shareholders?

Outlook Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (3.60%), Bank of New York Mellon Corp (0.10%), Advisor Group Holdings Inc. (0.05%) and Dfpg Investments LLC (0.12%). Company insiders that own Outlook Therapeutics stock include Kurt J Hilzinger, Lawrence A Kenyon and Randy H Thurman. View institutional ownership trends for Outlook Therapeutics.

Which institutional investors are buying Outlook Therapeutics stock?

OTLK stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC, Bank of New York Mellon Corp, Advisor Group Holdings Inc., and Dfpg Investments LLC. Company insiders that have bought Outlook Therapeutics stock in the last two years include Kurt J Hilzinger, Lawrence A Kenyon, and Randy H Thurman. View insider buying and selling activity for Outlook Therapeutics.

How do I buy shares of Outlook Therapeutics?

Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Outlook Therapeutics' stock price today?

One share of OTLK stock can currently be purchased for approximately $0.75.

How big of a company is Outlook Therapeutics?

Outlook Therapeutics has a market capitalization of $68.34 million and generates $8.15 million in revenue each year. The company earns $-34,520,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Outlook Therapeutics employs 56 workers across the globe.

What is Outlook Therapeutics' official website?

The official website for Outlook Therapeutics is www.outlooktherapeutics.com.

How can I contact Outlook Therapeutics?

Outlook Therapeutics' mailing address is 4260 U.S. ROUTE 1, MONMOUTH JUNCTION NJ, 08852. The company can be reached via phone at 609-619-3990 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.